Dreicer R, Kollmorgen T A, Smith R F, Williams R D
Department of Urology, University of Iowa College of Medicine, Iowa City.
J Urol. 1993 Sep;150(3):849-52. doi: 10.1016/s0022-5347(17)35630-6.
A total of 26 patients with locally advanced bladder cancer received chemotherapy consisting of cisplatin, methotrexate and vinblastine. Radical cystectomy was performed in 24 of 26 patients (92%) receiving neoadjuvant therapy, with a pathological complete response in 6 (23%) and pathological partial response in 1 (4%) for an overall response rate of 35% (95% confidence limits 17 to 56%). The overall median survival time is currently undefined. Of the patients 15 (58%) are alive with a median followup of 48.6 months. Response rates from this neoadjuvant chemotherapy appear to be similar to those reported with methotrexate, vinblastine, doxorubicin and cisplatin, and may represent a therapeutically equivalent regimen but neither may be curative in the majority of the patients.
共有26例局部晚期膀胱癌患者接受了由顺铂、甲氨蝶呤和长春碱组成的化疗。26例接受新辅助治疗的患者中有24例（92%）接受了根治性膀胱切除术，其中6例（23%）病理完全缓解，1例（4%）病理部分缓解，总缓解率为35%（95%置信区间为17%至56%）。目前总体中位生存时间尚未确定。15例（58%）患者存活，中位随访时间为48.6个月。这种新辅助化疗的缓解率似乎与甲氨蝶呤、长春碱、阿霉素和顺铂报道的缓解率相似，可能代表一种治疗等效方案，但在大多数患者中两者都无法治愈。
